CAM
NAVB

Capstone Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Capstone Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-532
Closed -$20K – 1737
2014
Q1 		$20K Hold
532
– – ﹤0.01% 1743
2013
Q4 		$22K Sell
532
-16
-3% -$626 ﹤0.01% 1865
2013
Q3 		$29K Hold
548
– – ﹤0.01% 1996
2013
Q2 		$29K Buy
+548
New +$27.4K ﹤0.01% 1950

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capstone Asset Management's NAVB Position: Q2 2014 in Review

Capstone Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2014, closing a stake of 532 shares — an estimated $20K sold.

Capstone Asset Management first reported a position in NAVB in Q2 2013 and held it in 4 quarters. The position peaked at $29K in Q3 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q2 2014.

  • Capstone Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2014 after selling out during the quarter.
  • Capstone Asset Management sold 532 Navidea Biopharmaceuticals Inc. shares in Q2 2014, an estimated $20K.
  • Capstone Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 4 quarters.
  • Capstone Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $29K in Q3 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2014.

Based on Capstone Asset Management's 13F filing for Q2 2014, filed 11 Jul 2014.